


FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 191891A		SERIAL NO. 08/525,870	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) DORN, ET AL.			
				FILING DATE Sep 8, 1995		GROUP ART UNIT 1201	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	2,949,022	6/28/60	SIEMER, ET AL. (I)	167	65		
	3,005,818	10/24/61	SIEMER, ET AL. (II)	260	247.2		
	3,458,509	7/29/69	LEVINE, ET AL.	260	243		
	3,506,673	4/14/70	WARAWA, ET AL.	260	294.7		
	3,541,090	11/17/70	HERLINGER, ET AL.	260	243		
	4,010,266	3/1/77	MCLOUGHLIN, ET AL.	424	248.4		
	4,360,519	11/23/82	WHITE, ET AL.	424	248.55		
	4,705,553	11/10/87	BUSCHMANN, ET AL.	71	76		
	4,782,054	11/1/88	REGNIER, ET AL.	514	235.2		
	4,943,578	7/24/90	NAYLOR, ET AL.	514	252		
	5,064,838	11/12/91	GARR, ET AL.	514	317		
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	0 360 390	3/28/90	EPO				
	0 436 334	7/10/91	EPO				
	0 499 313	8/19/92	EPO				
	0 528 495	2/24/93	EPO				
	0 533 280	3/24/93	EPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Siemer, et al., "Analgesic 1-phenyl-2,3 dimethyl-4-morpholinomethyl-3-pyrazolin-5-ones",					
		Chem. Abstracts, 56, (6), p. 5977 (1962)					
154		Sinkula, et al., "Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs", J.					
		Pharm. Sciences, 64 (2), pp. 181-210 (1975)					
154		Svensson, "Prodrugs: metabolism-based drug design", Pharmaceutisch Weekblad, 122, pp.					
		245-250, (1987)					
EXAMINER					DATE CONSIDERED		
					02/20/97		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

191891A

SERIAL NO.

08/525,870

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT(S)

P. DORN, ET AL.

FILING DATE

Sep 8, 1995

GROUP ART UNIT

1201

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,095,021	3/10/92	ZIPPLIES, ET AL.	167	65	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	2,534,015	4/27/84	FRANCE				
	WO 90/05525	5/31/90	WIPO				
	WO 90/05729	5/31/90	WIPO				
	WO 91/16899	12/12/91	WIPO				
	WO 92/01679	2/6/92	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

Wayne D. Hegel

DATE CONSIDERED

02-20-97

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

USCOMM-DC 80-3965

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)191692A
APPLICANT(S)

G. E. DORN, ET AL.

FILING DATE

9/8/95

GROUP ART UNIT

1201

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Advenier, et al., "Neurokinin A (NK2) Receptor Revisited with SR 48968...", Biochem. and Biophys. Res. Comm., 184(3), pp. 1418-1424 (1992).Balant, et al., "Prodrugs for the improvement of drug absorption via different routes of administration.", Eur. J. Drug Metab. Pharmacol., 15(2), pp. 143-153, (1990).Bodar, et al., "Novel Approaches in Prodrug Design", Drugs Future, VI(3), pp. 165-182 (1981).Bundgaard, "The double prodrug concept and its applications", Adv. Drug Deliv. Rev., 3 pp. 39-65, (1989).Edmonds-Ait, et al., "A Potent and Selective Non-Peptide Antagonist of the Neurokinin A (NK2) Receptor", Life Sciences, 50, pp. PL101-PL106 (1992).Frossard, et al., "Tachykinin Receptors and the Airways", Life Sciences, 49, pp. 1941-1953, (1991).Guthrie, et al., "The Use of Periodate-oxidised Glycosides in the Robinson-Scheffé...", J. Chem. Society, Vol C(1), pp. 62-66 (1967).Howson, et al., "An SAR Study for the Non-Peptide Substance P Receptor...", Bioorganic & Medicinal Chemistry Letters, 2(6), pp. 559-564, (1992).Lowe, et al., "The Discovery of (2S,3S)-cis-2-(Diphenylmethyl)-N-[(2-methoxyphenyl)methyl]...", J. Med. Chem., 35, pp. 2591-2600, (1992).McGormick, "Properties of Periodate-Oxidised Polysaccharides", Part VII. "...", J. Chem. Society, C(23), pp. 2121-27, (1966).Montgomery, et al., "2-Fluoropurine Ribonucleosides", J. Med. Chem., 13(3), pp. 421-7 (1970).Payan, et al., "Substance P Recognition by a Subset of Human T Lymphocytes", J. Clin. Invest., 74, 1532-1539 (1984).Peyronel, et al., "Synthesis of RP-67,580, a New Potent Nonpeptide Substance P Antagonist", Bioorganic and Med. Chem. Lett., 2(1), pp. 37-40, (1992).

EXAMINER

Floyd D. Higel

DATE CONSIDERED

02-20-97

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.